2010 Hema intro

Article

Visit ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists gave exclusive interviews and expert perspective reports on the highlights of this year’s meeting. See the links below for  Hematologic Cancers session coverage from hematologic malignancy authority Samuel M. Silver, MD, PhD, University of Michigan

Visit ONCOLOGY’s on-site coverage of the annual meeting: Internationally regarded oncologists gave exclusive interviews and expert perspective reports on the highlights of this year’s meeting. See the links below for  Hematologic Cancers session coverage from hematologic malignancy authority Samuel M. Silver, MD, PhD, University of Michigan

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content